

Barcelona, 4th September 2023

OTHER RELEVANT INFORMATION

Almirall acquires rights for an Alzheimer's product in Spain

Almirall, S.A. (the "Company"), in accordance with the provisions of Article 227 of Law 6/2023 of 17 March on the Securities Market and Investment Services, and related provisions, hereby gives notice of the following:

The execution of acquisition rights is for an Alzheimer's product in Spain. This agreement grants Almirall exclusive rights.

The product is a transdermal patch with rivastigmine to treat Alzheimer's Disease, increasing the level of neurotransmitter acetylcholine helping to reduce the symptoms of Alzheimer's. It brings Almirall the opportunity to reinforce its neurology business unit in Spain.

The transaction has been closed for an upfront payment of €45MM. This agreement also contemplates potential milestones up to €15MM.

Sincerely,

Pablo Divasson del Fraile
Investor Relations Department
investors@almirall.com